Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Builds Tarceva Inventory Following Iressa's Failed Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech has been building inventory for its non-small cell lung cancer agent Tarceva (erlotinib) following AstraZeneca's announcement that Iressa (gefitinib) failed to show a statistically significant survival benefit

You may also be interested in...



Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005

Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.

Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005

Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.

Genentech's Avastin Gaining Market Share In On- And Off-Label Indications

Avastin's share in the first-line metastatic colorectal cancer setting reached 55% in the fourth quarter, up from 42% in the third quarter. Off-label use in the second-line increased to 41%. An August "Dear Doctor" letter on thromboembolic events may have had an impact on slower-than-expected fourth quarter sales of the oncologic.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel